To the full analysis
Buyback calculator for WuXi Biologics (Cayman)
WuXi Biologics (Cayman) stock: key metrics
2269.HKWuXi Biologics (Cayman) had an operating margin of 30.5% and a return on invested capital (ROIC) of 13.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2014 | 37.1% | 15.9% | 12.6% |
| 2015 | 32.4% | 11.2% | 8.0% |
| 2016 | 39.3% | 20.4% | 14.3% |
| 2017 | 40.8% | 21.5% | 15.6% |
| 2018 | 40.2% | 34.6% | 24.9% |
| 2019 | 41.6% | 27.9% | 25.4% |
| 2020 | 45.1% | 26.8% | 30.1% |
| 2021 | 46.9% | 31.0% | 32.9% |
| 2022 | 44.0% | 28.4% | 29.0% |
| 2023 | 40.1% | 26.1% | 20.0% |
| 2024 | 41.0% | 26.6% | 18.0% |
| 2025 | 46.0% | 30.5% | 22.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2014 | 11.3% | 10.7% | 6.6% |
| 2015 | 30.5% | 9.8% | 3.3% |
| 2016 | 52.2% | 19.3% | 7.1% |
| 2017 | 6.3% | 18.2% | 5.2% |
| 2018 | 7.9% | 25.5% | 6.7% |
| 2019 | 7.9% | 16.2% | 5.8% |
| 2020 | 8.2% | 10.7% | 5.8% |
| 2021 | 10.5% | 13.5% | 7.7% |
| 2022 | 12.6% | 12.8% | 8.9% |
| 2023 | 8.4% | 11.0% | 6.0% |
| 2024 | 8.0% | 10.5% | 5.9% |
| 2025 | 10.4% | 13.1% | 7.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.